How are comparative effectiveness research and HTA applicable to the biopharmaceutical industry?

Understanding Comparative Effectiveness Research (CER)/Health Technology Assessment (HTA) inthe Biopharmaceutical Industry

June 23 from 1:00PM – 4:30PM in Boston

Health care reform has amplified interest in Comparative Effectiveness Research (CER)/Health Technology Assessment (HTA). CER/HTA may sound threatening without a realistic context for what it is, how it has evolved, what it is intended to do and its limitations. A brief introduction and overview of CER/HTA will be presented through lecture, interactive discussions and case study. This tutorial will present a perspective of CER/HTA in the context of clinical trials and health care policy and provide timely insights for today’s biopharmaceutical professionals.


Instructor(s):
Nancie E. Celini, DrPH,MPH
Chief Learning Consultant
CAB Inc., United States

Vadim Tantsyura, DrPH,MA,MS
Director, Data Management
Cincinnati Children's Hospital Medical Center, United States


What’s more…Receive $100 off of your DIA 2013 Annual Meeting registration by registering for two half day tutorials or one full day tutorial. Please note purchases must be made at the same time in order to receive the discount.

Visit www.diahome.org/DIA2013 for more details on the DIA 2013 Annual Meeting being held June 23-27 in Boston, MA.

Sign up for DIA's Global SmartBrief eNews for the latest in drug development innovations worldwide.